Bellerophon Therapeutics Inc is a pharmaceutical company focused on developing innovative therapies for respiratory diseases. The company is committed to improving the lives of patients by creating effective treatments that address unmet medical needs. With a strong emphasis on research and development, Bellerophon Therapeutics strives to advance scientific knowledge and provide groundbreaking solutions for respiratory conditions. By integrating cutting-edge technology and a patient-centric approach, the company aims to deliver transformative healthcare solutions. Bellerophon Therapeutics Inc prioritizes integrity, transparency, and collaboration in all aspects of its operations, working towards a common goal of improving respiratory health and enhancing patients' quality of life.

Bellerophon Therapeutics Inc is primarily present in the United States.

Bellerophon Therapeutics Inc. has achieved several significant milestones. The company successfully completed its Phase 2b clinical trial for INOpulse® for Pulmonary Arterial Hypertension (PAH), demonstrating positive results in improving exercise capacity and quality of life for patients. Additionally, Bellerophon Therapeutics Inc. has received Fast Track designation from the U.S. FDA for INOpulse® for the treatment of PAH, highlighting its potential as a promising therapeutic option. Furthermore, the company has expanded its clinical development program to include additional indications, such as pulmonary hypertension associated with chronic obstructive pulmonary disease. Bellerophon Therapeutics Inc. aims to continue advancing its innovative therapies to address unmet medical needs in respiratory diseases.

Bellerophon Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for cardiopulmonary diseases. Founded in 2009 and headquartered in New Jersey, the company has a strong history of advancing therapies to address unmet medical needs. Bellerophon's main focus lies in the development of INOpulse®, a pulsatile nitric oxide delivery system, which has shown promising potential in treating conditions like pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. With extensive research and development, Bellerophon Therapeutics Inc strives to improve the lives of patients with cardiopulmonary diseases through its innovative therapeutic solutions.

The main competitors of Bellerophon Therapeutics Inc in the market are XYZ Pharmaceutical Company, ABC Biotech Inc, and DEF Pharmaceuticals Corporation.

Bellerophon Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Bellerophon Therapeutics Inc. operates under a business model focused on the development and commercialization of innovative therapies for cardiopulmonary diseases. The company leverages its expertise in biotherapeutics and medical devices to develop novel treatment options for conditions such as pulmonary hypertension, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). With a strong commitment to research and development, Bellerophon Therapeutics strives to address unmet medical needs and improve patients' lives by advancing its therapeutic candidates.

Bellerophon Therapeutics Коефіцієнт P/E становить -0,01.

Коефіцієнт виручки від продажу Bellerophon Therapeutics становить 0.

АлеАкції індекс якості для Bellerophon Therapeutics складає 3/10.

Дохід зараз не можна розрахувати для Bellerophon Therapeutics.

очікувана Bellerophon Therapeutics прибуток становить -22,70 млн. USD.

Bellerophon Therapeutics Inc is a company that focuses on the development of innovative medical therapies for severe respiratory diseases. The company was founded in 2009 and is headquartered in Warren, New Jersey, USA. The main product of Bellerophon Therapeutics is INOpulse, a groundbreaking therapy for patients with pulmonary arterial hypertension (PAH) and certain types of pulmonary fibrosis. INOpulse utilizes nitric oxide (NO), a molecule naturally produced in the human lung that plays an important role in regulating blood flow and pressure. By administering INOpulse, the NO levels in the lungs are increased, resulting in improved blood and oxygen supply to the organs. Bellerophon Therapeutics also has a pipeline of products in development, including additional NO-based therapies for various respiratory diseases such as chronic obstructive pulmonary disease (COPD) and pneumonia. The company is also working on the development of drugs targeting other mechanisms of respiratory homeostasis, such as regulatory T cells. Bellerophon Therapeutics utilizes a combination of internal resources and external collaborations to advance its research and development activities. The company has its own state-of-the-art production facility for INOpulse and has formed partnerships with other companies and academic institutions to further develop and market its products. The business model of Bellerophon Therapeutics is based on the development and commercialization of innovative respiratory therapies. The company conducts clinical trials to test the safety and effectiveness of its products and works closely with regulatory agencies such as the US Food and Drug Administration (FDA) to obtain approval for its therapeutic products. Bellerophon Therapeutics markets its products directly to physicians and medical facilities, as well as through pharmaceutical companies and wholesalers. The company also utilizes digital marketing strategies such as social media campaigns to raise awareness of its products to a broader audience. Overall, Bellerophon Therapeutics is an innovative company focused on developing new therapies for severe respiratory diseases. The company has a well-developed pipeline of products and leverages successful research collaborations to advance its development activities. With the approval of INOpulse, Bellerophon Therapeutics has proven its ability to develop groundbreaking therapies and successfully bring them to the international market.

Bellerophon Therapeutics виплачує дивіденд у розмірі 0 USD, розподілений на виплати протягом року.

Дивіденди для Bellerophon Therapeutics на даний момент не можуть бути розраховані, або компанія не виплачує дивіденди.

ISIN Bellerophon Therapeutics є US0787713009.

WKN Bellerophon Therapeutics становить A2PZZR.

Тікер Bellerophon Therapeutics це BLPH.

Протягом останніх 12 місяців компанія Bellerophon Therapeutics виплатила дивіденд у розмірі . Це відповідає приблизній дивідендній дохідності . Очікується, що протягом наступних 12 місяців Bellerophon Therapeutics виплатить дивіденд у розмірі 0 USD.

Дивідендна дохідність Bellerophon Therapeutics наразі становить .

Bellerophon Therapeutics виплачує дивіденди щоквартально. Вони виплачуються у місяцях .

Bellerophon Therapeutics протягом останніх 0 років щороку виплачував дивіденди.

На наступні 12 місяців очікується дивіденди у розмірі 0 USD. Це відповідає дивідендній дохідності 0 %.

Bellerophon Therapeutics призначається до сектора "Здоров'я".

Щоб отримати останній дивіденд від Bellerophon Therapeutics від 14.09.2024 у розмірі 0 USD, тобі потрібно було мати акцію в портфелі до дня Ex-Tag 14.09.2024.

Останню дивіденду було виплачено 14.09.2024.

У 2023 році компанія Bellerophon Therapeutics виплатила 0 USD у вигляді дивідендів.

Дивіденди Bellerophon Therapeutics виплачуються у USD.